Ironwood Pharma (IRWD) Misses Q2 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ironwood Pharma (IRWD) Misses Q2 EPS by 1c

Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update

August 4, 2016 4:10 PM EDT

Ironwood revenue increased 96% to $54.4 million in 2Q 2016 compared to 2Q 2015

LINZESS® (linaclotide) U.S. net sales increased 34% to $150.5 million in 2Q 2016 over 2Q 2015; net profit for the brand increased to $58 million from $15 million

On track to launch two priority franchise products: ZURAMPIC® (lesinurad) in October 2016 for hyperuricemia associated with uncontrolled gout and 72 mcg linaclotide in early 2017 for chronic idiopathic constipation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More